이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Lee's Pharmaceutical Holdings 미래 성장

Future 기준 확인 1/6

Lee's Pharmaceutical Holdings의 수익이 증가할 것으로 예상됨입니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Pharmaceuticals 수익 성장	10.7%
매출 성장률	16.1%
향후 자기자본 수익률	4.0%
애널리스트 커버리지	Low
마지막 업데이트	16 Apr 2024

최근 미래 성장 업데이트

Recent updates

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

May 21

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20

Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Mar 17

Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

Feb 22

What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 29

What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?

Jan 12

Have Insiders Sold Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Recently?

Dec 22

Don't Ignore The Fact That This Insider Just Sold Some Shares In Lee's Pharmaceutical Holdings Limited (HKG:950)

Dec 08

Is Lee's Pharmaceutical Holdings Limited's (HKG:950) Recent Price Movement Underpinned By Its Weak Fundamentals?

Dec 01

Is Lee's Pharmaceutical Holdings Limited (HKG:950) A Strong Dividend Stock?

Nov 18

수익 및 매출 성장 예측

SEHK:950 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (HKD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2025	1,461	N/A	N/A	N/A	1
12/31/2024	1,278	N/A	N/A	N/A	1
12/31/2023	1,053	17	-30	110	N/A
9/30/2023	980	5	N/A	N/A	N/A
6/30/2023	1,096	39	-133	70	N/A
3/31/2023	1,165	39	N/A	N/A	N/A
12/31/2022	1,233	51	70	284	N/A
9/30/2022	1,350	-119	N/A	N/A	N/A
6/30/2022	1,331	-140	103	317	N/A
3/31/2022	1,308	1,966	N/A	N/A	N/A
12/31/2021	1,266	1,987	-160	211	N/A
9/30/2021	1,275	2,176	N/A	N/A	N/A
6/30/2021	1,244	2,188	-65	394	N/A
3/31/2021	1,227	130	N/A	N/A	N/A
12/31/2020	1,217	129	-139	219	N/A
9/30/2020	1,199	167	N/A	N/A	N/A
6/30/2020	1,168	184	-142	179	N/A
3/31/2020	1,209	118	N/A	N/A	N/A
12/31/2019	1,219	126	39	400	N/A
9/30/2019	1,185	301	N/A	N/A	N/A
6/30/2019	1,177	331	-43	309	N/A
3/31/2019	1,139	395	N/A	N/A	N/A
12/31/2018	1,138	418	27	321	N/A
9/30/2018	1,126	243	N/A	N/A	N/A
6/30/2018	1,101	233	45	447	N/A
3/31/2018	1,064	256	N/A	N/A	N/A
12/31/2017	1,009	233	98	366	N/A
9/30/2017	981	245	N/A	N/A	N/A
6/30/2017	955	256	N/A	358	N/A
3/31/2017	930	245	N/A	N/A	N/A
12/31/2016	930	252	N/A	395	N/A
9/30/2016	911	259	N/A	N/A	N/A
6/30/2016	894	247	N/A	309	N/A
3/31/2016	917	242	N/A	N/A	N/A
12/31/2015	922	229	N/A	160	N/A
9/30/2015	976	221	N/A	N/A	N/A
6/30/2015	990	209	N/A	140	N/A
3/31/2015	979	191	N/A	N/A	N/A
12/31/2014	955	193	N/A	220	N/A
9/30/2014	874	175	N/A	N/A	N/A
6/30/2014	805	164	N/A	255	N/A
3/31/2014	755	160	N/A	N/A	N/A
12/31/2013	697	150	N/A	179	N/A
9/30/2013	658	140	N/A	N/A	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 950 의 예상 수익 증가율이 절약률( 2.2% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: 950 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 950 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: 950 의 수익(연간 16.1% ) Hong Kong 시장( 7.8% 보다 빠르게 성장할 것으로 예상됩니다. 7.8% 연간).

고성장 수익: 950 의 수익(연간 16.1% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 950 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 4 %).

Lee's Pharmaceutical Holdings 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Price target decreased to HK$1.80

Price target decreased to HK$1.80

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Price target decreased to HK$4.85

Recent updates

Board Member recently bought HK$120k worth of stock

Board Member recently bought HK$61k worth of stock

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

Upcoming dividend of HK$0.01 per share

Board Member recently bought HK$130k worth of stock

Less than half of directors are independent

Final dividend of HK$0.01 announced

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Board Member recently bought HK$123k worth of stock

New minor risk - Market cap size

Board Member recently bought HK$75k worth of stock

Investor sentiment improves as stock rises 15%

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Board Member recently bought HK$50k worth of stock

Board Member recently bought HK$113k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$347k worth of stock

Investor sentiment improves as stock rises 17%

Senior Adviser & Non-Executive Director recently bought HK$110k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$76k worth of stock

Investor sentiment improves as stock rises 18%

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023

First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022)

New minor risk - Market cap size

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director

Upcoming dividend of HK$0.01 per share at 1.3% yield

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021)

Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List

Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021)

Price target decreased to HK$1.80

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022

Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa

Price target decreased to HK$1.80

Upcoming dividend of HK$0.01 per share

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022

Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021)

Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Board Member recently bought HK$231k worth of stock

Lee's Pharmaceutical Holdings Limited Announces That Teglutik Obtains Drug Registration Certificate

Board Member recently bought HK$381k worth of stock

First quarter 2022 earnings released: EPS: HK$0.035 (vs HK$0.07 in 1Q 2021)

Lee's Pharmaceutical Holdings Limited's Natulan Obtains Drug Registration Certificate

Upcoming dividend of HK$0.031 per share

Lee's Pharmaceutical Holdings Limited to Report Q1, 2022 Results on May 26, 2022

Price target decreased to HK$4.85

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 19, 2022

Full year 2021 earnings released: EPS: HK$3.38 (vs HK$0.22 in FY 2020)

Lee's Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022

Price target decreased to HK$5.30

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Lee's Pharmaceutical Holdings Limited Obtains Approval from the Center for Drug Evaluation

Second quarter 2021 earnings released: EPS HK$3.59 (vs HK$0.097 in 2Q 2020)

Investor sentiment deteriorated over the past week

Non-Executive Director Simon Miles Ball has left the company

Price target decreased to HK$6.42

First quarter 2021 earnings released: EPS HK$0.07 (vs HK$0.068 in 1Q 2020)

Price target decreased to HK$6.92